Journal of Clinical Oncology, Vol 10, 558-563, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol

CR Nichols, J Andersen, HM Lazarus, H Fisher, J Greer, EA Stadtmauer, PJ Loehrer and DL Trump
Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis.

PURPOSE: A phase II trial was undertaken to assess the feasibility, toxicity, and efficacy of high-dose carboplatin and etoposide with autologous bone marrow transplantation in patients with relapsed or refractory germ cell tumors. PATIENTS AND METHODS: Forty patients with recurrent germ cell cancer received carboplatin 500 mg/m2 and etoposide 400 mg/m2 given at 7, 5, and 3 days before marrow infusion. Autologous marrow infusion (day 0) was accomplished using one half of the bone marrow harvested before chemotherapy. Patients who achieved a complete or partial response with the first cycle of treatment received a second identical cycle of chemotherapy followed by infusion of the remaining cryopreserved bone marrow. RESULTS: Objective responses were obtained in 17 of the 38 patients (45%) assessable for response, including eight partial and nine complete remissions. Five of these patients remain in continuous complete remission with minimal follow-up of 1 year. Toxicity encountered was primarily hematologic, and five patients (13%) died of treatment-related complications. Significant toxicities often seen with high-dose cisplatin (ototoxicity, neurotoxicity, and renal toxicity) were manageable in this regimen of high-dose carboplatin. CONCLUSIONS: This trial confirms the curative potential of high-dose carboplatin and etoposide in highly refractory germ cell cancer.

This article has been cited by other articles:

				G. Sonpavde, T. E. Hutson, and B. J. Roth Management of Recurrent Testicular Germ Cell Tumors Oncologist, January 1, 2007; 12(1): 51 - 61. [Abstract] [Full Text] [PDF]

				H. Sakurai, H. Asamura, K. Suzuki, S.-i. Watanabe, and R. Tsuchiya Management of Primary Malignant Germ Cell Tumor of the Mediastinum Jpn. J. Clin. Oncol., July 1, 2004; 34(7): 386 - 392. [Abstract] [Full Text] [PDF]

				S. Modak, S. Gardner, I. J. Dunkel, C. Balmaceda, M. K. Rosenblum, D. C. Miller, S. Halpern, and J. L. Finlay Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors J. Clin. Oncol., May 15, 2004; 22(10): 1934 - 1943. [Abstract] [Full Text] [PDF]

				P. Porcu, S. Bhatia, M. Sharma, and L. H. Einhorn Results of Treatment After Relapse From High-Dose Chemotherapy in Germ Cell Tumors J. Clin. Oncol., March 13, 2000; 18(6): 1181 - 1186. [Abstract] [Full Text] [PDF]

				J. O. Armitage Bone Marrow Transplantation N. Engl. J. Med., March 24, 1994; 330(12): 827 - 838. [Full Text]